IBD in the COVID-19 era: the value of international collaboration.
作者信息
Brenner Erica J, Ungaro Ryan C, Colombel Jean-Frederic, Kappelman Michael D
机构信息
Department of Pediatric Gastroenterology, University of North Carolina Children's Hospital, Chapel Hill, NC 27514, USA.
The Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):887-888. doi: 10.1016/S2468-1253(20)30269-7.
Abstract
摘要
相似文献
1
IBD in the COVID-19 era: the value of international collaboration.新冠疫情时代的炎症性肠病：国际合作的价值
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):887-888. doi: 10.1016/S2468-1253(20)30269-7.
2
Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.新冠疫情时代的数据可视化：SECURE-IBD注册研究的交互式地图
Am J Gastroenterol. 2020 Nov;115(11):1923-1924. doi: 10.14309/ajg.0000000000000953.
3
Management of inflammatory bowel diseases in the wake of COVID-19 pandemic.新冠疫情之后炎症性肠病的管理
J Gastroenterol Hepatol. 2020 Aug;35(8):1449-1450. doi: 10.1111/jgh.15056. Epub 2020 Apr 26.
4
COVID-19 and Inflammatory Bowel Disease: Questions on Incidence, Severity, and Impact of Treatment?新型冠状病毒肺炎与炎症性肠病：关于发病率、严重程度及治疗影响的问题？
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2637-2638. doi: 10.1016/j.cgh.2020.06.002. Epub 2020 Jun 6.
5
Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance.COVID-19 大流行时期炎症性肠病患者的管理：巴西一家三级转诊中心的指导建议。
Clinics (Sao Paulo). 2020 Apr 17;75:e1909. doi: 10.6061/clinics/2020/e1909. eCollection 2020.
6
Implications of COVID-19 for patients with pre-existing digestive diseases.2019冠状病毒病对患有既往消化系统疾病患者的影响。
Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427. doi: 10.1016/S2468-1253(20)30076-5. Epub 2020 Mar 11.
7
Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study.美国炎症性肠病患者发生重症2019冠状病毒病的风险：一项多中心研究网络研究
Gastroenterology. 2020 Oct;159(4):1575-1578.e4. doi: 10.1053/j.gastro.2020.06.003. Epub 2020 Jun 6.
8
Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty.COVID-19 大流行期间炎症性肠病患者的实用管理：澳大利亚胃肠病学会炎症性肠病学院专家评论。
Intern Med J. 2020 Jul;50(7):798-804. doi: 10.1111/imj.14889.
9
Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak.雾化吸入在炎症性肠病管理中的应用：新冠疫情期间炎症性肠病发作的一个罕见病例
Inflamm Bowel Dis. 2020 Sep 18;26(10):e128-e129. doi: 10.1093/ibd/izaa184.
10
Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic.建立安全的院外输液中心可能会改善新冠疫情期间炎症性肠病患者的护理质量。
Inflamm Bowel Dis. 2020 Oct 23;26(11):e140. doi: 10.1093/ibd/izaa246.
引用本文的文献
1
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.评估 COVID-19 细胞因子风暴综合征患者中使用英夫利昔单抗/托珠单抗与托珠单抗的效果。
Sci Rep. 2023 Apr 20;13(1):6456. doi: 10.1038/s41598-023-33484-6.
2
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.免疫介导的炎症性疾病患者对 SARS-CoV-2 mRNA 疫苗的免疫应答迅速减弱。
JCI Insight. 2022 Jun 8;7(11):e159721. doi: 10.1172/jci.insight.159721.
3
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis.炎症性肠病患者的 COVID-19 多波疫情：时间趋势分析。
Inflamm Bowel Dis. 2022 Nov 2;28(11):1687-1695. doi: 10.1093/ibd/izab339.
4
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.加拿大克罗恩病与结肠炎协会《2021年新冠疫情对加拿大炎症性肠病的影响：执行摘要》
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S1-S9. doi: 10.1093/jcag/gwab027. eCollection 2021 Dec.
5
Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation.全球传染病研究合作应对危机：通过合作增强能力和包容性。
Global Health. 2021 Jul 26;17(1):84. doi: 10.1186/s12992-021-00731-2.
6
Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess.COVID-19 的内分泌风险因素：内源性和外源性糖皮质激素过多。
Rev Endocr Metab Disord. 2022 Apr;23(2):233-250. doi: 10.1007/s11154-021-09670-0. Epub 2021 Jul 9.
7
The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?新冠病毒与自身免疫的交叉点：我们目前的理解是什么？
Pathog Immun. 2021 Mar 8;6(1):31-54. doi: 10.20411/pai.v6i1.417. eCollection 2021.
8
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.新型冠状病毒病 2019（COVID-19）在风湿性疾病患者中的流行病学和结局。
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101657. doi: 10.1016/j.berh.2020.101657. Epub 2020 Dec 23.
本文引用的文献
1
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
2
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
Zotero 插件